Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...

By Kunal Das and Puyaan Singh July 21 (Reuters) - Agios Pharmaceuticals said on Tuesday it is discontinuing development of ...

Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...

Hepcidin and ferritin-based indices help identify patients with active inflammatory bowel disease who are less likely to respond to iron therapy.

First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from ...

Agios Pharmaceuticals said tebapivat fell short of expectations in a Phase 2 test in sickle cell disease. It’s the latest in ...

Stock drops after development setback Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company ...

Updated American Cancer Society guidance is reshaping colorectal cancer screening, expanding testing options and raising ...

A study of the long-term health impact of the Lahaina wildfires is inspiring a new model for disaster recovery and support.

The continent should take the matter of resistance very, very seriously...Resistance should be seen as an emergency situation.” ...

A laser-based innovation could allow electron microscopes to reveal biological structures that have long remained beyond ...